Diamyd nets $45 million up front from J&J for late-stage diabetes therapy
This article was originally published in Scrip
Executive Summary
Diamyd Medical of Sweden is to receive $45 million up front and potentially another $580 million in development and sales milestones following the signing of a development and commercialisation deal with J&J's Ortho-McNeil-Janssen Pharmaceuticals for its novel Diamyd diabetes therapy.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.